The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Induced Expression of p16INK4a Inhibits Both CDK4- and CDK2-Associated Kinase Activity by Reassortment of Cyclin-CDK-Inhibitor Complexes
Open accessAbstract
To investigate the mode of action of the p16(INK4a) tumor suppressor protein, we have established U2-OS cells in which the expression of p16(INK4a) can be regulated by addition or removal of isopropyl-beta-D-thiogalactopyranoside. As expected, induction of p16(INK4a) results in a G1 cell cycle arrest by inhibiting phosphorylation of the retinoblastoma protein (pRb) by the cyclin-dependent kinases CDK4 and CDK6. However, induction of p16(INK4a) also causes marked inhibition of CDK2 activity. In the case of cyclin E-CDK2, this is brought about by reassortment of cyclin, CDK, and CDK-inhibitor complexes, particularly those involving p27(KIP1). Size fractionation of the cellular lysates reveals that a substantial proportion of CDK4 participates in active kinase complexes of around 200 kDa. Upon induction of p16(INK4a), this complex is partly dissociated, and the majority of CDK4 is found in lower-molecular-weight fractions consistent with the formation of a binary complex with p16(INK4a). Sequestration of CDK4 by p16(INK4a) allows cyclin D1 to associate increasingly with CDK2, without affecting its interactions with the CIP/KIP inhibitors. Thus, upon the induction of p16(INK4a), p27(KIP1) appears to switch its allegiance from CDK4 to CDK2, and the accompanying reassortment of components leads to the inhibition of cyclin E-CDK2 by p27(KIP1) and p21(CIP1). Significantly, p16(INK4a) itself does not appear to form higher-order complexes, and the overwhelming majority remains either free or forms binary associations with CDK4 and CDK6.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, p16 upregulation in the presence of p21 synergistically induces irreversible cell cycle arrest by inhibiting both CDK2 and CDK4/6 [32].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [32]
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Ashburner, M. (1989) · Cold Spring Harbor Laboratory eBooks · Cited by 6,756
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Antibodies: A laboratory manual
J.L. (1989) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(89)90307-1 · Cited by 5,141
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Inhibitors of mammalian G1 cyclin-dependent kinases.Preprint
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,242
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,208
Polyák, K., Lee, M.-H., Erdjument‐Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Flagged first, then by citations
Research works printed but not linked: 16
- Adachi M., 1997, Blood, 90, 126, 10.1182/blood.V90.1.126.126_126_137 · DOI
- Bates S., 1994, Oncogene, 9, 71
- Diller L., 1990, Mol. Cell. Biol., 10, 5772
- Fotedar R., 1996, Oncogene, 12, 2155
- Goubin F., 1995, Oncogene, 10, 2281
- Hall M., 1995, Oncogene, 11, 1581
- Jen J., 1994, Cancer Res., 54, 6353
- Loughran O., 1996, Oncogene, 13, 561
- Lukas J., 1995, Oncogene, 10, 2125
- Matsushime H., 1994, Mol. Cell. Biol., 14, 2066
- Meyerson M., 1994, Mol. Cell. Biol., 14, 2077
- Reznikoff C. A., 1996, Cancer Res., 56, 2886
- Shapiro G. I., 1995, Cancer Res., 55, 6200
- Soos T. J., 1996, Cell Growth Differ., 7, 135
- Stone S., 1995, Oncogene, 11, 987
- Vogt M., 1998, Cell Growth Differ., 9, 139
Cited by
Sorted by citations
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.
Gartel, A. L., & Tyner, A. L. (2002) · PubMed · Cited by 918
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 565
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 472
Metadata
- Authors
- McConnell, B. B., Gregory, F. J., Stott, F. J., Hara, E., & Peters, G.
- Affiliations
- Imperial Cancer Research Fund Laboratories, London WC2A 3PX, United Kingdom
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1999-03-01
- Volume
- 19
- Issue
- 3
- Pages
- 1981-1989
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC83991
- OpenAlex
- W1923683854
- Cited by
- 238
- References
- 81
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 4 · 2023: 9 · 2022: 9 · 2021: 7 · 2020: 3 · 2019: 6 · 2017: 10 · 2016: 5 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 8
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16INK4a, CDK4, CDK2, cyclin-dependent kinase inhibition, p27, p21, cyclin E, cyclin D1, retinoblastoma protein phosphorylation, G1 cell cycle arrest, tumor suppressor mechanism, U2OS cells, inducible gene expression
- MeSH terms
- Cell Cycle, Cell Division, Enzyme Inhibitors, Humans, Microtubule-Associated Proteins, Proto-Oncogene Proteins, Time Factors, Tumor Cells, Cultured, Cyclins, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Proteins, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase Inhibitor p27, Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
